Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Estrella Immunopharma ( (ESLA) ) is now available.
On June 5, 2025, Estrella Immunopharma announced the activation of a second clinical site for its STARLIGHT-1 Phase I/II trial, which evaluates the EB103 T-cell therapy in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Partnering with the Baylor Research Institute in Dallas, Texas, this expansion aims to accelerate development and increase patient access to EB103, potentially enhancing Estrella’s industry positioning and impact on stakeholders by broadening the trial’s reach and improving treatment options for advanced NHL.
The most recent analyst rating on (ESLA) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Estrella Immunopharma stock, see the ESLA Stock Forecast page.
More about Estrella Immunopharma
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases. The company’s mission is to leverage the human immune system’s evolutionary power to transform the lives of patients battling cancer and other diseases, with lead product candidates like EB103 and EB104 utilizing Eureka’s ARTEMIS® technology.
Average Trading Volume: 205,844
Technical Sentiment Signal: Sell
Current Market Cap: $30.17M
Find detailed analytics on ESLA stock on TipRanks’ Stock Analysis page.